The Latest Breaking News from Eli Lilly

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved.

Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.

Investors could snag these two stocks as BofA flags the companies as well-positioned winners in an uncertain quarter.

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Netflix is among the stocks with most bullish analyst ratings. (Netflix)

Trump tariff news: President Trump's latest tariffs took effect Wednesday while China stepped up retaliation. Treasury yields are worrisome. Walmart and Delta Air pulled some guidance, citing tariff uncertainty.

The Trump administration says it will raise Medicare Advantage payments sharply, good news for Humana, UnitedHealth and other health insurers.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.

A single dose of lepodisiran dramatically lowered dangerous lipoprotein(a) levels for up to a year, offering new hope for heart disease treatment.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.